Best of Gastroenterology Report 2012

Click here to view the full Best of Gastroenterology 2012 Report.

Click here to view the full Best of Gastroenterology 2012 Report.

The top stories from 2012, as identified by CARE Gastroenterology Working Group Steering Commitee and covered in this review include:

  1. PROFILE 1007: Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

  2. PARAMOUNT: Phase III Study of Maintenance Pemetrexed (Pem) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC Immediately Following Induction Treatment With Pem Plus Cisplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  3. LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Afatinib Versus Pemetrexed and Cisplatin as First-Line Treatment for Patients With Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations

LUX-Lung 3: Symptom and Health-Related Quality of Life Results From a Randomized Phase III Study In 1st-Line Advanced NSCLC Patients Harbouring EGFR

  1. Dacomitinib (PF-00299804): An Irreversible Pan-HER Tyrosine Kinase Inhibitor (TKI), for First-Line Treatment of EGFR-Mutant, or HER2-Mutant or HER2-Amplified Lung Cancers

  2. FASTACT-II: A Randomized Placebo-Controlled Phase III Study of Intercalated Erlotinib With Gemcitabine/ Platinum in First-Line Advanced Non-Small Cell Lung Cancer (NSCLC) 

Below is the link the full report:

Click here for the full report.

Click here for the full report.